NuGenerex Immuno-oncology, Inc. (NGIO)
NuGenerex Immuno-oncology will go public soon, but the exact IPO date is still unknown.
Stock Price: $8.50 - $9.50
Current IPO price range
Chart not available yet
Data will show when the stock starts trading.
| Market Cap | 952.70M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -4.63M |
| Shares Out | 105.86M |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About NGIO
NuGenerex Immuno-oncology is focused on the regulation of the immune system to treat cancer and infectious diseases. To that end, we are developing immunotherapeutic products and vaccines based on our proprietary, patented platform technology, Ii-Key. With the Ii-Key vaccine technology, we are able to activate the immune system against target molecules, whether those targets are tumor associated antigens (TAAs) in cancer cells, or viral or bacterial proteins in infectious disease pathogens. Through our 20+ year history of research and developme... [Read more...]
Industry
Pharmaceutical Preparations
Founded
1993
CEO
Joseph Moscato
Employees
6
Stock Exchange
NASDAQ
Ticker Symbol
NGIO
Financial Performance
Financial StatementsNews
NuGenerex Immuno-oncology IPO Registration Document (S-1)
NuGenerex Immuno-oncology, Inc. has filed to go public with an IPO on the NASDAQ.